Kenneth T. Mills - Dec 19, 2023 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Dec 19, 2023
Transactions value $
-$720,990
Form type
4
Date filed
12/21/2023, 01:38 PM
Previous filing
Jan 5, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $164K +43.5K +12.24% $3.76* 399K Dec 19, 2023 Direct F1
transaction RGNX Common Stock Options Exercise $1.28K +1.5K +0.38% $0.85* 400K Dec 19, 2023 Direct F1
transaction RGNX Common Stock Sale -$886K -45K -11.24% $19.69 355K Dec 19, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -43.5K -18.93% $0.00 186K Dec 19, 2023 Common Stock 43.5K $3.76 Direct F1, F3
transaction RGNX Stock Options (Right to Buy) Options Exercise $0 -1.5K -3.97% $0.00 36.3K Dec 19, 2023 Common Stock 1.5K $0.85 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $19.48 to $20.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 43,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 9, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
F4 The previously granted option, representing a right to purchase a total of 1,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on September 24, 2015, and the balance vested in equal monthly installments over the 36 months thereafter.